Submitted by Anonymous (not verified) on 14 October 2026 - 9:35
Opinion/decision on a Paediatric investigation plan (PIP): Tevimbra, tislelizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: EMA/PE/0000235505
Source: